Total Payments
$43,318
2024 Payments
$23,579
Companies
12
Transactions
49
Medicare Patients
88
Medicare Billing
$25,643
Payment Breakdown by Category
Consulting$23,272 (53.7%)
Research$17,123 (39.5%)
Food & Beverage$1,104 (2.5%)
Other$1,028 (2.4%)
Travel$777.89 (1.8%)
Education$14.18 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $23,272 | 6 | 53.7% |
| Unspecified | $17,123 | 15 | 39.5% |
| Food and Beverage | $1,104 | 22 | 2.5% |
| Honoraria | $1,028 | 1 | 2.4% |
| Travel and Lodging | $777.89 | 4 | 1.8% |
| Education | $14.18 | 1 | 0.0% |
Payments by Type
General
$26,196
34 transactions
Research
$17,123
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Servier BioInnovation | $17,123 | 15 | $0 (2024) |
| SERVIER PHARMACEUTICALS LLC | $10,946 | 5 | $0 (2024) |
| ABBVIE INC. | $7,428 | 8 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $5,882 | 3 | $0 (2024) |
| Rigel Pharmaceuticals, Inc. | $1,173 | 4 | $0 (2023) |
| Genentech USA, Inc. | $349.12 | 5 | $0 (2024) |
| Astellas Pharma US Inc | $158.88 | 2 | $0 (2024) |
| ADC Therapeutics America, Inc. | $150.00 | 1 | $0 (2024) |
| Amgen Inc. | $40.22 | 2 | $0 (2019) |
| Celgene Corporation | $35.27 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23,579 | 23 | SERVIER PHARMACEUTICALS LLC ($10,946) |
| 2023 | $19,654 | 22 | Servier BioInnovation ($10,802) |
| 2021 | $31.34 | 1 | Genentech USA, Inc. ($31.34) |
| 2019 | $54.40 | 3 | Amgen Inc. ($40.22) |
All Payment Transactions
49 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | SERVIER PHARMACEUTICALS LLC | — | Consulting Fee | Cash or cash equivalent | $3,360.00 | General |
| 12/17/2024 | Servier BioInnovation | — | — | Cash or cash equivalent | $1,356.88 | Research |
| Study: Outcomes by frailty in IC-ineligible newly diagnosed AML a real-world evidence comparison by treatment with hypomethylating agents + ivosidenib or venetoclax | ||||||
| 12/17/2024 | Servier BioInnovation | — | — | Cash or cash equivalent | $1,356.88 | Research |
| Study: Outcomes by frailty in IC-ineligible newly diagnosed AML a real-world evidence comparison by treatment with hypomethylating agents + ivosidenib or venetoclax | ||||||
| 12/17/2024 | Servier BioInnovation | — | — | Cash or cash equivalent | $320.38 | Research |
| Study: Outcomes by frailty in IC-ineligible newly diagnosed AML a real-world evidence comparison by treatment with hypomethylating agents + ivosidenib or venetoclax | ||||||
| 12/08/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $150.00 | General |
| 12/08/2024 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $15.24 | General |
| Category: BioOncology | ||||||
| 11/22/2024 | SERVIER PHARMACEUTICALS LLC | — | Consulting Fee | Cash or cash equivalent | $7,280.00 | General |
| 11/22/2024 | SERVIER PHARMACEUTICALS LLC | — | Travel and Lodging | In-kind items and services | $155.95 | General |
| 11/22/2024 | SERVIER PHARMACEUTICALS LLC | — | Travel and Lodging | In-kind items and services | $146.14 | General |
| 10/14/2024 | Servier BioInnovation | — | — | Cash or cash equivalent | $855.31 | Research |
| Study: Waiting for mutational test results does not delay time to treatment for newly diagnosed AML ineligible for intensive chemo | ||||||
| 10/14/2024 | Servier BioInnovation | — | — | Cash or cash equivalent | $855.31 | Research |
| Study: Waiting for mutational test results does not delay time to treatment for newly diagnosed AML ineligible for intensive chemo | ||||||
| 10/14/2024 | Servier BioInnovation | — | — | Cash or cash equivalent | $547.86 | Research |
| Study: Improved Hematologic Recovery with Ivosidenib in Patients with mIDH1 Relapsed or Refractory MDS: Results from a Phase 1 Substudy | ||||||
| 10/14/2024 | Servier BioInnovation | — | — | Cash or cash equivalent | $436.25 | Research |
| Study: Waiting for mutational test results does not delay time to treatment for newly diagnosed AML ineligible for intensive chemo | ||||||
| 10/14/2024 | Servier BioInnovation | — | — | Cash or cash equivalent | $330.63 | Research |
| Study: Outcomes by frailty in IC-ineligible newly diagnosed AML a real-world evidence comparison by treatment with hypomethylating agents + ivosidenib or venetoclax | ||||||
| 10/14/2024 | Servier BioInnovation | — | — | Cash or cash equivalent | $261.25 | Research |
| Study: Waiting for mutational test results does not delay time to treatment for newly diagnosed AML ineligible for intensive chemo | ||||||
| 09/11/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,730.00 | General |
| 07/27/2024 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $153.82 | General |
| Category: BioOncology | ||||||
| 06/15/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $75.66 | General |
| Category: Oncology | ||||||
| 06/15/2024 | Celgene Corporation | ONUREG (Drug) | Food and Beverage | Cash or cash equivalent | $13.57 | General |
| Category: Oncology | ||||||
| 05/28/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,076.00 | General |
| 04/15/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,076.00 | General |
| 04/05/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $21.70 | General |
| 03/05/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $3.88 | General |
| Category: Oncology | ||||||
| 12/18/2023 | Servier BioInnovation | — | — | Cash or cash equivalent | $996.20 | Research |
| Study: A Comparison of Acute Myeloid Leukemia, AML, Regimens: Hypomethylating Agents Combined with Ivosidenib or Venetoclax in Newly Diagnosed Patients with IDH1 Mutations; A Real-World Evidence Study | ||||||
| 12/18/2023 | Servier BioInnovation | — | — | Cash or cash equivalent | $996.20 | Research |
| Study: A Comparison of Acute Myeloid Leukemia, AML, Regimens: Hypomethylating Agents Combined with Ivosidenib or Venetoclax in Newly Diagnosed Patients with IDH1 Mutations; A Real-World Evidence Study | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Comparison of Acute Myeloid Leukemia, AML, Regimens: Hypomethylating Agents Combined with Ivosidenib or Venetoclax in Newly Diagnosed Patients with IDH1 Mutations; A Real-World Evidence Study | Servier BioInnovation | $9,135 | 5 |
| Outcomes by frailty in IC-ineligible newly diagnosed AML a real-world evidence comparison by treatment with hypomethylating agents + ivosidenib or venetoclax | Servier BioInnovation | $3,365 | 4 |
| Waiting for mutational test results does not delay time to treatment for newly diagnosed AML ineligible for intensive chemo | Servier BioInnovation | $2,408 | 4 |
| A Comparison of Acute Myeloid Leukemia, AML, Regimens: Hypomethylating Agents Combined with Ivosidenib or Venetoclax in Newly-Diagnosed Patients with IDH1 Mutations; A Real-World Evidence Study | Servier BioInnovation | $1,667 | 1 |
| Improved Hematologic Recovery with Ivosidenib in Patients with mIDH1 Relapsed or Refractory MDS: Results from a Phase 1 Substudy | Servier BioInnovation | $547.86 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 88 | 307 | $80,432 | $25,643 |
Total Patients
88
Total Services
307
Medicare Billing
$25,643
Procedure Codes
4
All Medicare Procedures & Services
4 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 32 | 150 | $40,872 | $14,184 | 34.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 27 | 66 | $18,766 | $4,950 | 26.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 76 | $13,882 | $4,794 | 34.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 13 | 15 | $6,912 | $1,715 | 24.8% |
About Dr. Curtis Lachowiez, M.D
Dr. Curtis Lachowiez, M.D is a Internal Medicine healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/01/2015. The National Provider Identifier (NPI) number assigned to this provider is 1194110585.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Curtis Lachowiez, M.D has received a total of $43,318 in payments from pharmaceutical and medical device companies, with $23,579 received in 2024. These payments were reported across 49 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($23,272).
As a Medicare-enrolled provider, Lachowiez has provided services to 88 Medicare beneficiaries, totaling 307 services with total Medicare billing of $25,643. Data is available for 1 year (2023–2023), covering 4 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology
- Location Portland, OR
- Active Since 04/01/2015
- Last Updated 05/26/2022
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1194110585
Products in Payments
- VENCLEXTA (Drug) $7,428
- Rezlidhia (Drug) $1,173
- Venclexta (Biological) $217.99
- Xospata (Drug) $158.88
- VENCLEXTA (Biological) $31.34
- ELZONRIS (Drug) $19.29
- FERAHEME (Drug) $14.18
- ONUREG (Drug) $13.57
- Blincyto (Biological) $11.79
- Tibsovo (Drug) $3.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Portland
Nananda Col, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M
Stephen Yau, M.d, M.D
Internal Medicine — Payments: $980,262
Internal Medicine $980,262
Ethan Korngold, Md, MD
Internal Medicine — Payments: $610,759
Internal Medicine $610,759
Dr. Firas Zahr, Md, MD
Internal Medicine — Payments: $543,624
Internal Medicine $543,624
Dr. Martin Moehlen, M.d, M.D
Internal Medicine — Payments: $318,908
Internal Medicine $318,908
Scott Chadderdon, Md, MD
Internal Medicine — Payments: $189,078
Internal Medicine $189,078